🇺🇸 FDA
Patent

US 10093742

Multispecific GITR-binding fusion proteins and methods of use thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 10093742 (Multispecific GITR-binding fusion proteins and methods of use thereof) held by Inhibrx, Inc. expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx, Inc.
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
57
CPC classes
A61K, A61K2039/505, A61P, A61P35/00